Silver Book Fact

A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.

Shea B, Wells G, Cranney A, Zytaruk N, et al. Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis. Endocr Rev. 2002; 23(4): 552-9. http://edrv.endojournals.org/cgi/content/full/23/4/552

Reference

Title
Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis
Publication
Endocr Rev
Publication Date
2002
Authors
Shea B, Wells G, Cranney A, Zytaruk N, et al
Volume & Issue
Volume 23, Issue 4
Pages
552-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.